一刀切是否适用?2018年Leapfrog集团肺癌手术医院与外科医生最低手术量阈值的评估
本研究基于纽约州和佛罗里达州2007至2013年住院数据库,分析27841例接受肺叶或全肺切除术的肺癌患者,评估2018年Leapfrog集团设定的医院年手术量≥40例和外科医生年手术量≥15例的最低阈值对年轻健康与年老体弱患者结局的适用性。结果显示医院手术量对并发症和死亡率的影响大于外科医生手术量,尤其对年老体弱患者,提示Leapfrog指南应更强调医院手术量而非外科医生手术量,且对年轻健康患者可能相关性较低。
要点
- 医院手术量增加与死亡率、并发症和延长住院时间降低相关,外科医生手术量也相关但效应较弱。
- 低容量外科医生(<15例/年)联合低容量医院(<40例/年)治疗的患者死亡风险最高(2.5%)。
- 年老体弱患者(年龄>77岁,Elixhauser合并症指数>3)在高容量外科医生治疗下死亡率最高(12%),但高医院容量具保护作用。
核心结论
- 医院手术量对肺癌手术发病率和死亡率的影响大于外科医生手术量,尤其对年老体弱患者。
- Leapfrog集团的手术量指南应更强调医院手术量而非外科医生手术量,且对年轻健康患者可能相关性较低。
研究设计与样本
- 回顾性队列研究,使用纽约州和佛罗里达州2007至2013年住院数据库。
- 纳入27841例接受肺叶切除术或全肺切除术的肺癌患者,其中男性13277例(48%)。
- 采用多变量logit模型评估住院死亡率、并发症和延长住院时间。
主要发现
- 患者中位年龄69岁(四分位距61-77),总死亡率为2.1%。
- 低容量外科医生(<15例/年)联合低容量医院(<40例/年)治疗的患者死亡风险最高(2.5%),但年轻健康患者队列死亡率<2%。
- 年老体弱患者在高容量外科医生治疗下死亡率最高(12%),而更高医院容量具保护作用。
关键数值与推荐
- 2018年Leapfrog集团设定医院年肺癌手术量最低阈值为40例,外科医生年手术量最低阈值为15例。
- 年轻健康定义为年龄18-60岁且Elixhauser合并症指数<1;年老体弱定义为年龄>77岁且Elixhauser合并症指数>3。
临床怎么用
- 临床选择肺癌手术机构时,应优先考虑医院年手术量而非仅关注外科医生手术量。
- 对于年老体弱患者,尤其应确保在高容量医院接受手术以降低死亡和并发症风险。
- 对年轻健康患者,Leapfrog手术量阈值的相关性可能较低,可个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2018, the Leapfrog Group set minimum annual lung cancer surgery hospital and surgeon volume thresholds of 40 and 15, respectively. We examined whether outcomes associated with these Leapfrog Group volume thresholds are comparable for patients at the extremes of age and comorbidities. METHODS: We assessed lung cancer patients undergoing lobectomy or pneumonectomy in the New York and Florida State Inpatient Databases for 2007 to 2013. Multivariate logit models evaluated in-hospital mortality, complications, and prolonged length of stay. Median surgeon and hospital volumes were compared between "younger-healthier" (age 18-60 years, Elixhauser Comorbidity Index <1) and "older-sicker" patients (age >77 years, Elixhauser Comorbidity Index >3). RESULTS: The 27,841 patients included 13,277 men (48%). The median patient age was 69 years (interquartile range, 61-77), and mortality was 2.1%. Patients treated by both low-volume surgeons (<15 annual cases) and at low-volume hospitals (<40) had the greatest risk of mortality (2.5%), except for the cohort of younger-healthier patients (mortality <2%). Mortality for older-sicker patients was highest for high-volume surgeons (12%), although higher hospital volume was protective. Increasing hospital volume was associated with decreased mortality (odds ratio [OR], 0.997; 95% confidence interval [CI], 0.995-0.998; P = .0103), complications (OR, 0.998; 95% CI, 0.997-0.999; P < .001), and prolonged length of stay (OR, 0.998; 95% CI, 0.997-1.00; P = .01); similarly, higher surgeon volume was associated with decreased mortality (OR, 0.997; 95% CI, 0.99-1.00; P = .03), complications (OR, 0.997; 95% CI, 0.994-1.00; P = .02), and prolonged length of stay (OR, 0.991; 95% CI, 0.986-0.995; P < .01). CONCLUSIONS: Hospital volume has a greater effect on morbidity and mortality than surgeon volume especially for older-sicker patients, suggesting that Leapfrog Group volume guidelines should emphasize hospital volume over surgeon volume and may be less relevant for younger-healthier patients.
引用
- Clark JM, Cooke DT, Chin DL, et al. Does one size fit all? An evaluation of the 2018 Leapfrog Group minimal hospital and surgeon volume thresholds for lung surgery. J Thorac Cardiovasc Surg. 2019. PMID: 31740117. doi:10.1016/j.jtcvs.2019.09.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。